SAN FRANCISCO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) were presented at the T-Cell Lymphoma Forum being held January 26-28, 2012 in San Francisco, CA. In addition, case studies were presented on two patients with relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) who were treated with ADCETRIS. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is not approved for use in CTCL or PTCL-NOS.
